U.S. Cloning And Mutagenesis Market Size & Outlook

The cloning and mutagenesis market in the United States is expected to reach a projected revenue of US$ 2,456.1 million by 2030. A compound annual growth rate of 17.5% is expected of the United States cloning and mutagenesis market from 2023 to 2030.
Revenue, 2022 (US$M)
$675.0
Forecast, 2030 (US$M)
$2,456.1
CAGR, 2023 - 2030
17.5%
Report Coverage
U.S.

U.S. cloning and mutagenesis market, 2018-2030 (US$M)

U.S.

U.S. cloning and mutagenesis market highlights

  • The U.S. cloning and mutagenesis market generated a revenue of USD 675.0 million in 2022 and is expected to reach USD 2,456.1 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 17.5% from 2023 to 2030.
  • In terms of segment, topo pcr cloning was the largest revenue generating technology in 2022.
  • Site-Directed Mutagenesis is the most lucrative technology segment registering the fastest growth during the forecast period.


Cloning and mutagenesis market data book summary

Market revenue in 2022USD 675.0 million
Market revenue in 2030USD 2,456.1 million
Growth rate17.5% (CAGR from 2022 to 2030)
Largest segmentTopo pcr cloning
Fastest growing segmentSite-Directed Mutagenesis
Historical data2018 - 2021
Base year2022
Forecast period2023 - 2030
Quantitative unitsRevenue in USD million
Market segmentationTopo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis
Key market players worldwideAgilent Technologies Inc, Thermo Fisher Scientific Inc, New England Biolabs, Takara Bio Inc, Merck KGaA, Promega, Bio-Rad Laboratories Inc, Danaher Corp, Assay Genie, Jena Bioscience, TransGen Biotech


Other key industry trends

  • In terms of revenue, U.S. accounted for 29.3% of the global cloning and mutagenesis market in 2022.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. cloning and mutagenesis market is projected to lead the regional market in terms of revenue in 2030.
  • Canada is the fastest growing regional market in North America and is projected to reach USD 563.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cloning and Mutagenesis Market Companies

Name Profile # Employees HQ Website

U.S. cloning and mutagenesis market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cloning and mutagenesis market will help companies and investors design strategic landscapes.


Topo pcr cloning was the largest segment with a revenue share of 29.07% in 2022. Horizon Databook has segmented the U.S. cloning and mutagenesis market based on topo pcr cloning, blunt end cloning, seamless cloning, site-directed mutagenesis covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to U.S. cloning and mutagenesis market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of U.S. cloning and mutagenesis market databook

  • Our clientele includes a mix of cloning and mutagenesis market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cloning and mutagenesis market, including forecasts for subscribers. This country databook contains high-level insights into U.S. cloning and mutagenesis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

U.S. cloning mutagenesis market report size, by technology, 2018-2030 (US$M)

U.S. Cloning and Mutagenesis Market Share, 2022 & 2030 (US$M)

U.S. cloning mutagenesis market report size, by technology, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more